InsidersTradesSigma
Vivoryon Therapeutics N.V. Stock: price and directors' dealings · Netherlands · AFM
Track the Vivoryon Therapeutics N.V. stock price and the full directors' dealings record of the company, a publicly traded company based in Netherlands. Shares trade on NL NL, under the oversight of AFM. Operating in the Healthcare & Pharma sector, Vivoryon Therapeutics N.V. has recorded 39 reports. Market capitalisation: €32.3m. The latest transaction was filed on 17 April 2026 (Purchase). Among the most active insiders: F. Weber. Every trade is free.
39
Insider Decl.
0
Thresholds
€2m
36 ops.
Buy Volume
€240,878
3 ops.
Sell Volume
33Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 April 2026
Declarations39 total
150,000 shares0OptieAFM:192632
Ideal exit: 12 Jan 2027 (T+270)
150,000 shares0OptieAFM:192625
Ideal exit: 12 Jan 2027 (T+270)
128,809 shares@ €1.8113.2% of flowGewoon aandeelAFM:184550
Ideal exit: 4 Sept 2026 (T+270)
20,000 shares0OptieAFM:182044
Ideal exit: 13 Jul 2026 (T+270)
25,000 shares0OptieAFM:176906
Ideal exit: 27 Mar 2026 (T+270)
25,000 shares0OptieAFM:176907
Ideal exit: 27 Mar 2026 (T+270)
25,000 shares0OptieAFM:176908
Ideal exit: 27 Mar 2026 (T+270)
50,000 shares0OptieAFM:176529
Ideal exit: 21 Mar 2026 (T+270)
-128,809 shares@ €1.8113.2% of flowGewoon aandeelAFM:173752
75,000 shares0OptieAFM:171766
Ideal exit: 10 Dec 2025 (T+270)
25,000 shares0OptieAFM:160246
Ideal exit: 18 Mar 2025 (T+270)
25,000 shares0OptieAFM:160247
Ideal exit: 18 Mar 2025 (T+270)
25,000 shares0OptieAFM:160248
Ideal exit: 18 Mar 2025 (T+270)
120,000 shares0OptieAFM:159529
Ideal exit: 3 Mar 2025 (T+270)
-3,867 shares@ €2.00100.0% of flowGewoon aandeelAFM:155125
90,000 shares0OptieAFM:152998
Ideal exit: 6 Oct 2024 (T+270)
25 of 39 declarations
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the Amsterdam Stock Exchange (XAMS).
